Sylvain L.
- Country
- France
- Department
- Oncologie Medicale
Research Overview
- ISIdE: Open label, multicentric, single-arm phase IIIB trial to evaluate the safety and efficacy of sacituzumab govitecan in triple negative metastatic breast cancer patients with a biomarker analysis.
- A Phase 3 Study of MK-2870 Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced or Metastatic Urothelial Carcinoma
- De-escalation of endocrine therapy in postmenopausal women with low-risk HR+ HER2- low Luminal A early breast cancer: a single-arm study of omission versus combination therapy
Data & Insights
Has run more than one trial at 415 of 771 partner sites.
Specializations
Breast Cancer Research
Extensive focus on multiple breast cancer subtypes, including triple-negative breast cancer, HER2-positive breast cancer, and hormone receptor-positive disease.
- Early-stage disease treatment optimization
- Metastatic breast cancer therapies
- Novel therapeutic combinations
Particular expertise in investigating targeted therapies and immunotherapy approaches for breast cancer treatment.
Genitourinary Oncology
Specialized research in urological cancers, with significant work in renal cell carcinoma, prostate cancer, and urothelial carcinoma.
- Advanced kidney cancer treatments
- Prostate cancer hormone therapy
- Bladder cancer immunotherapy
Focus on developing innovative treatment strategies for metastatic disease states.
Precision Medicine
Implementation of biomarker-driven treatment approaches and molecular targeting strategies across multiple cancer types.
- Circulating tumor DNA analysis
- Targeted therapy selection
- Treatment resistance mechanisms
Emphasis on personalized treatment approaches based on molecular and genetic profiles.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.